Atul — A Lalbhai-Group Cycle: Peak, Trough, and Back to a Record

A note on sources up front. Unlike the other companies in this batch, Atul does not host earnings calls — it publishes presentations, but no transcripts exist on screener or BSE. This chronicle is therefore built from Atul’s annual reports (FY23–FY25), which are unusually candid and serve as the management’s primary narrative, plus the screener financial snapshot for the FY26 numbers (the FY26 annual report is not yet out). The result is a year-by-year arc rather than the quarter-by-quarter “said vs delivered” you’ll find in the others — there are simply no quarterly management commitments on record to line up.

The State of Play

Atul is a 78-year-old Lalbhai-group chemical company that makes a wide spread of things — crop-protection actives, pharmaceutical intermediates, aromatics, dyes and pigments, and epoxy resins. Over the last four years it ran a full chemical cycle: a disappointing FY23 already off its 2020–21 highs, a sharp price-driven trough in FY24, a volume-and-margin recovery in FY25, and then in FY26 a clean record — sales of ₹6,274 crore and profit of ₹689 crore, the highest in over a decade. Throughout, the defining feature is the balance sheet: Atul is essentially debt-free (₹183 crore of borrowings against ₹6,192 crore of reserves), generating ₹851 crore of free cash flow in FY26. The stock trades at about 29 times earnings — a milder valuation than its specialty-chemical peers, reflecting a steadier, more diversified, lower-growth profile.

The Company

Atul is a “diversified and integrated Indian chemical company,” part of the Lalbhai group — one of India’s oldest business houses, founded by Kasturbhai Lalbhai (the firm started as Atul Products in 1947, renamed Atul Ltd in 1996). Chairman and Managing Director is Sunil Siddharth Lalbhai. It runs two reporting segments across “9 Businesses”:

• Life Science Chemicals (LSC) — Crop Protection (bulk actives + a growing retail brand business), Pharmaceuticals & Intermediates, and Aromatics-I.
• Performance & Other Chemicals (POC) — Aromatics-II, Bulk Chemicals & Intermediates, Colors (dyes and pigments), and Polymers (epoxy resins, both performance materials and retail).

POC is the larger segment (~65–68% of sales); LSC the more volatile one. The business has historically been B2B and is gingerly extending into B2C (retail crop-care and polymer brands, plus an array of small ventures from date palms to a hospital). It is export-oriented (sales outside India run ~₹1,800–2,300 crore, into 80-plus countries), and — the single most important recurring fact — heavily exposed to Chinese price competition in Colors and Polymers especially.

Ownership is stable: promoters hold ~45.2%, edging gently up. Domestic institutions are the largest outside block (~26%), with foreign funds (~7.5%) having made a round trip over three years. Returns sit at ROCE ~15%, ROE ~11.5% — recovered, but management is careful to keep reminding shareholders these are still well below the FY20–21 peaks of 27% EBITDA margin and 28–34% return on capital.

The Story So Far

Read across three annual reports plus the FY26 results, Atul’s recent history is one clean cycle, narrated by a management that is unusually willing to say plainly when a year fell short.

FY23 — “our endeavour fell short”

The FY23 report — written in the company’s 75th-anniversary year — is candid about disappointment. Sunil Lalbhai called it “one of the harder years”: standalone EBITDA margin and return on capital fell to 18% and 19%, down from earlier bests of 26% and 28%. Consolidated revenue was ₹5,428 crore and profit ₹507 crore. Underneath, the segments diverged sharply. Life Science Chemicals had a great year — crop-protection bulk actives surged 25% on a post-disruption commodity-price spike, lifting segment profit from ₹179 crore to ₹423 crore. But Performance & Other Chemicals had a bad one — its profit collapsed from ₹576 crore to ₹240 crore, dragged down by Colors (down 22% on weak denim and European paint demand) and Polymers (epoxy margins squeezed by “cheaper imports and new entrants”). The China-led pricing overhang, the villain of the whole period, was already named. The forward commitment was a ₹1,350 crore multi-year capex programme to be completed by Q4 FY25, expected to add over ₹1,500 crore of annual sales at full utilisation. The year also marked Atul’s highest-ever capex (~₹900 crore) and a large ₹360 crore buy-back.

FY24 — the trough, and it was price, not demand

FY24 was the down year, and management’s framing of why is the key to the whole cycle: the decline was almost entirely about collapsing prices, not falling volumes. As the Directors’ Report put it, “the decline was the outcome of decrease in price realisation in India and outside by 19% and increase in volume by 5%.” Consolidated revenue fell 13% to ₹4,726 crore and profit dropped 34% to ₹324 crore; return on net worth halved to ~8%. The reversal was sharpest exactly where FY23 had boomed — crop-protection bulk actives fell 48% to ₹491 crore as customers worked off high-cost inventory and Chinese supply rose. Two new investments made it worse before they made it better: Atul Products’ new 300-tonne-per-day caustic-soda plant (commissioned December 2023) lost ₹32 crore on start-up troubles, and the Anaven monochloroacetic-acid joint venture lost ₹51 crore running below capacity. Exports contracted 23% — the steepest drop of the three years. The reassuring counter-narrative management leaned on: volumes were still rising, so the trough was price-cyclical, not structural.

FY25 — broad-based recovery

FY25 was the rebound. Sunil Lalbhai’s plain summary: “2024-25 was a better fiscal for our Company, although not the best.” Consolidated revenue rose 18% (volume +17%) to a then-record ₹5,583 crore, EBITDA jumped 47% to ₹1,022 crore (margin back to 18%), and profit recovered 54% to ₹499 crore. The recovery was broad — crop-protection bulk actives bounced back 28%, Colors and Polymers both grew double digits, and the two problem children turned: Atul Products’ caustic plant swung from a loss to ₹97 crore of EBITDA, and Anaven turned EBITDA-positive (though its parent loan stayed overdue). A clean quality milestone: all three pharma sites cleared US FDA inspections with zero observations. Strategically, the posture flipped from building capacity to filling it — management set an explicit target of ₹2,500 crore of additional sales to be extracted from the now-completed investment base. Capex stepped right down to ₹216 crore, and the balance sheet sat on ₹691 crore of net cash. The first appearance of a new worry, which management foregrounded for the first time: tariffs and protectionism.

FY26 — a record (from the numbers, ahead of the annual report)

The FY26 annual report isn’t out yet, but the quarterly results tell a clear story: the recovery extended into a genuine record. Full-year sales reached ₹6,274 crore and net profit ₹689 crore — the highest profit in the twelve years on record, and a meaningful step above FY25. Operating margin held at 16% (still below the 22–25% of FY20–21, the “north star” management keeps citing), quarterly sales rose every quarter through the year, and cash generation was the best in the series — ₹1,023 crore from operations and ₹851 crore of free cash flow. The one blemish in the otherwise improving picture: working-capital days roughly doubled, to 165 from the historical 50–77 range — a stretch worth watching against the strong profit and cash. The balance sheet stayed pristine (₹183 crore of debt, ₹4 crore of quarterly interest). In short, FY26 looks like the year the ₹2,500 crore “latent sales” thesis from FY25 began converting into the numbers — with the caveat that, absent an earnings call or the annual report, the drivers behind the FY26 record can’t yet be attributed to specific businesses.

Where Things Stand

As of the latest available data (FY26 results), Atul is a recovered, cash-rich, conservatively run diversified chemical company at a record profit but still short of its margin peaks. The throughlines across the cycle are consistent: volumes have generally held or grown while prices — pressured by Chinese supply in Colors, Polymers and crop-protection actives — have been the swing factor; one capex super-cycle (the ₹1,350 crore FY23 programme) has been built and is now being harvested for utilisation rather than extended; and the balance sheet has stayed near-debt-free and cash-generative throughout, funding steady dividends and occasional buy-backs. The forward questions — which, without earnings calls, the market will have to read from results and the eventual annual report — are whether margins can climb back toward the high-20s the company benchmarks itself against, whether the working-capital stretch in FY26 reverses, how the newer tariff/protectionism dynamic cuts (Atul is both an exporter and a beneficiary of import protection in some lines), and whether the long-gestating B2C and group-entity bets ever move the needle. The shape of the business is steadier and more diversified than its specialty-chemical peers — and the valuation, at 29 times earnings, reflects that more modest, lower-volatility profile.

The Four Checks

1. Quality and moat. A well-run, conservatively financed business with only a modest moat. Atul’s edges are real but defensive: 78 years of accumulated chemistry across nine businesses, backward integration (the new caustic-soda plant feeds its own chains), regulatory credentials (three pharma sites through US FDA with zero observations), and first-in-India positions in products like para-Cresol and Resorcinol. But the recurring villain of its own annual reports gives the game away — Chinese supply sets the price in Colors, Polymers and crop-protection actives, and FY24 showed what that means: volumes grew 5% while realisations fell 19% and profit dropped by a third. A business whose prices are set by someone else’s capacity is, in those lines at least, a price-taker with good manners. Call it a diversified mid-tier chemical franchise — durable as an institution, thin as a moat.

2. Returns on incremental capital and runway. Moderate, and well off the peaks management itself keeps citing. ROCE sits at 14.9% and ROE at 11.5% in the June 2026 snapshot, recovering from a trough of 9% in FY24 but far below the 28–34% return on capital of FY20–21; three-year average ROE is just 9.2%, and five-year sales growth is 11% — lumpy, not compounding. The runway exists but is defined: the ₹1,350 crore capex programme is built, and the stated prize is ₹2,500 crore of latent sales from filling it — FY26’s record (₹6,274 crore of sales, ₹689 crore of profit) suggests that harvest has begun. Whether incremental returns climb back toward the old peaks depends on pricing power Atul demonstrably does not control. Decent returns, real but bounded runway.

3. Capital allocation for the stage. The strongest of the four checks. Management ran one disciplined capex super-cycle — ₹900 crore in FY23, stepping down to ₹498 crore and then ₹216 crore as the build finished — and then explicitly switched from building capacity to filling it, rather than piling on more. The balance sheet has stayed near-debt-free throughout (₹183 crore of borrowings against ₹6,192 crore of reserves), dividends are steady (payout 13–19%), and there have been genuine buy-backs: ₹360 crore in FY23 and ₹50 crore in FY24, executed at an average of about ₹6,935 — roughly today’s price. The quibbles: a scatter of small diversifications (date palms, a hospital, dairy, many shell subsidiaries) that consume attention if not much capital, two investments (the caustic plant, the Anaven JV) that bled before turning, and a working-capital stretch to 165 days in FY26 that is yet to be explained. Rational, shareholder-aware, slightly busy at the edges.

4. Price. Full, and arguably demanding for the economics on offer. As of the June 2026 snapshot, the stock trades at ₹6,656 — a P/E of 28.8 on record FY26 earnings and 3.14 times book — for a business earning 14.9% ROCE with 11% five-year sales growth. The market is paying a quality-compounder multiple for a cyclical that has just printed its best year; the bull case requires margins to keep climbing from 16% toward the 22–25% of FY20–21, which is exactly the journey China pricing has interrupted before. The milder-than-peers multiple is fair as a relative observation, but in absolute terms nearly 29 times cyclically-recovered earnings leaves little room for the next down-leg of a cycle this company has reliably ridden.

Sources

• Earnings-call transcripts: none read — Atul does not host earnings calls (no transcripts available on screener or BSE; only investor presentations exist). This chronicle has no quarter-by-quarter management commentary as a result, and is built from annual reports plus the financial snapshot.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25. The FY24 chairman’s letter was image-based and didn’t extract; the equivalent framing was taken from that year’s Directors’ Report.
• Financial snapshot: screener.in (consolidated, ATUL), logged-out session, fetched 2026-06-07 — the source for all FY26 figures (the FY26 annual report is not yet published).
• Research dump: vault/Sources/Earnings/Atul Ltd/ (_profile_digest.md, _ar_digest.md, annual-report sections, _snapshot.json, _manifest.json). Not published.